Sudhakar R. Chintharlapalli, Ph.D.
Affiliations: | 2006 | Texas A & M University, College Station, TX, United States |
Area:
BiochemistryGoogle:
"Sudhakar Chintharlapalli"Parents
Sign in to add mentor| Stephen H. Safe | grad student | 2006 | Texas A & M | |
| (New mechanism-based anticancer drugs that act as orphan nuclear receptor agonists.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Singhal M, Gengenbacher N, La Porta S, et al. (2020) Preclinical validation of a novel metastasis-inhibiting Tie1 function-blocking antibody. Embo Molecular Medicine. e11164 |
| Li Z, Korhonen EA, Merlini A, et al. (2020) Angiopoietin-2 blockade ameliorates autoimmune neuroinflammation by inhibiting leukocyte recruitment into the CNS. The Journal of Clinical Investigation |
| Chintharlapalli S, Fischl A, Yu CP, et al. (2020) Abstract 1675: Enhanced antitumor effect of dual EGFR and VEGFR2 inhibition in EGFR-mutated non-small cell lung cancer (NSCLC) patient-derived tumor xenograft (PDX) models Cancer Research. 80: 1675-1675 |
| Fischl AS, Wang X, Falcon BL, et al. (2019) Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition. Molecular Cancer Therapeutics |
| Emmerson PJ, Duffin KL, Chintharlapalli S, et al. (2018) GDF15 and Growth Control. Frontiers in Physiology. 9: 1712 |
| Swearingen M, Falcon B, Chintharlapalli S, et al. (2018) An Endothelial Cell/Mesenchymal Stem Cell Coculture Cord Formation Assay to Model Vascular Biology In Vitro. Methods of Molecular Biology. 1683: 371-382 |
| Lee L, Huber L, Stewart J, et al. (2017) Evaluation of AFP expression as a predictive marker for response to anti-VEGFR-2 inhibition. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 28: iii19-iii20 |
| Um SL, Peek VL, Stephens JR, et al. (2017) Abstract 519: Antitumor activity of MET antibody emibetuzumab (LY2875358) in combination with EGFR inhibitors in erlotinib resistant (ER) xenograft mouse models Cancer Research. 77: 519-519 |
| Tetreault J, Chintharlapalli S, Leung D, et al. (2017) Abstract 3090: LY3207447, a tetravalent bispecific antibody targeting VEGFR2 and angiopoietin-2, provides a more efficient anti-angiogenic therapy and an alternative for combination Cancer Research. 77: 3090-3090 |
| Bodenmiller DM, Stewart JA, Evans GF, et al. (2017) Abstract 1823: Characterization of the anti-angiogenic properties of merestinib (LY2801653), an oncokinase inhibitor Cancer Research. 77: 1823-1823 |